DiaSys enters Chinese market via Vastec Medical deal:
This article was originally published in Clinica
DiaSys has signed a three-year exclusive agreement with Vastec Medical, a Hong Kong and China-based medical products distribution company. Under the terms of the agreement, Vastec will distribute and service DiaSys' urine sediment workstations throughout China and Hong Kong. The deal, which initially provides for a minimum order of 36 workstations, also gives Vastec first refusal to distribute future DiaSys products in China and Hong Kong. Vastec's managing director K S Ho says laboratory operating costs are making urine sediment analysis a difficult test to justify in China and Hong Kong. DiaSys' R/S series workstations provide standardisation and automation at affordable prices, Mr Ho adds.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.